How Norwich Will Invest the Medtech Convergence Fund

Norwich Ventures, of which Aaron Sandoski is co-founder & managing director, recently closed the $90 million Medtech Convergence Fund. The firm intends to invest the fund in startups whose technologies embody the convergence of AI, data, or telehealth with traditional engineering. The pandemic, however, has changed the outlook for everyone, including VCs. Join this webinar to learn about Norwich’s approach to investing in the current climate.

Early-Stage Healthtech Investing

Ali Farahanchi is Managing Director at DHVC, an early-stage tech and life science fund in Palo Alto. With more than $650M assets under management and 100+ companies in its portfolio, DHVC invests in variety of areas in healthcare including therapeutics, diagnostics and tools, and digital health, with strong emphasis on novel mechanisms and data-driven platforms. Previously Ali has worked in research and in consulting roles in semiconductor and healthcare industries, and has obtained graduate degrees in engineering and management from MIT and University of Chicago.

How to Prepare to Sell Your Life Science or Medtech Company

To ensure a successful sale of your startup you need to start planning early. Several issues are key. Among them: how to maximize value; how to manage stakeholders; and how to close the deal, which is everything once you decide to sell. To learn how to do it right—as well as hard-learned lessons about what happens if you don’t—join us on Thursday, February 20 to hear from Sam Williams, a partner in corporate law at the firm Brown Rudnick.